Cambridge Technologies is an independent custom vaccine company specializing in solutions for animal health issues. Utilizing state-of-the-art molecular diagnostic and manufacturing techniques, the company collaborates with veterinarians and livestock producers to address emerging health concerns.
The company's modern laboratory, staffed with diagnostic and research scientists, is dedicated to personalized service and employs advanced techniques such as metagenomics, genetic sequencing, qPCR, culture, sensitivity, and serology. This expertise enables Cambridge Technologies to precisely determine isolates required for custom vaccine production, keeping the company at the forefront of isolate identification and characterization.
With a USDA-licensed 37,000-square-foot manufacturing facility boasting a state-of-the-art fermentation suite, Cambridge Technologies formulates and produces customized vaccines tailored to the specific needs of its customers. The vaccine production team brings extensive experience in diagnostics, R&D, quality control, regulatory affairs, and both commercial and custom vaccine production, ensuring high-quality, tailored solutions.
Established in 2015 and headquartered in the United States, Cambridge Technologies operates in the pharmaceutical industry. Despite no publicly disclosed recent investments or involved investors, the company's focus on innovation and personalized service positions it as a potential contender in the evolving field of custom vaccine development.
There is no investment information
No recent news or press coverage available for Cambridge Technologies .